Intervention
Time-Restricted Eating
Confining all daily calories to a fixed daily window, typically 16:8, without necessarily reducing total intake.
Summary Does time-restricted eating improve health or help with weight loss? Show / hide ↓
Time-restricted eating means eating all your daily food within a set window, often 8 hours, and fasting for the remaining 16. In the largest 12-week trial, 141 adults with overweight or obesity lost no more weight than people eating three regular meals, and they lost more muscle in their arms and legs. Another 12-week study in adults with metabolic syndrome, a group of health problems linked to diabetes and heart disease, found that eating within roughly 14 hours lowered HbA1c, a measure of average blood sugar, by 0.10 percentage points. A review of 23 trials found small improvements in fasting blood sugar and insulin resistance, meaning the body has difficulty using insulin effectively. Most studies lasted only 8 to 12 weeks, so the long-term effects remain unclear.
What this means for you: Time-restricted eating does not reliably improve weight loss and may reduce muscle along with body weight. It may offer a small blood-sugar benefit for people with metabolic risk, but the evidence is conflicting.
conflicting evidenceTime-restricted eating (TRE) compresses all daily calories into a fixed window, most commonly 16:8 (eat for 8 hours, fast for 16), without necessarily reducing total calories. It is the most self-experimenter-friendly fasting variant because it requires no calorie counting, only a clock.
The largest and most rigorous test is the TREAT trial, run by Lowe and colleagues at UCSF and the University of Hawaii and published in JAMA Internal Medicine: 141 adults with overweight or obesity were randomized to 16:8 TRE or a structured three-meals-a-day control, 105 completed the 12-week trial [1]. The headline result: no significant difference in weight loss between TRE and the control group. TRE did not beat simply eating three meals a day when calories were not separately controlled.
The more clinically useful finding comes from a 2024 NIH-funded trial by Manoogian, Taub, and colleagues (Salk Institute and UC San Diego) in adults with metabolic syndrome, published in Annals of Internal Medicine: a roughly 14.2-hour eating window improved HbA1c by 0.10 percentage points (95% CI -0.19 to -0.003) relative to control, a modest but statistically real glycemic benefit in a population selected for metabolic risk rather than general population weight loss [2]. This is the kind of result that supports TRE as a metabolic-health tool in an at-risk population, distinct from its weak performance as a general weight-loss method.
The featured counter-finding, and it is a genuine one, not a minor caveat: in the TREAT trial, the TRE group lost more appendicular lean mass (muscle in the arms and legs) than the control group over the same 12 weeks [1]. A time-restricted eating window that produces no extra weight loss but does produce extra muscle loss is a bad trade, particularly for older adults or anyone already at risk of sarcopenia. This finding gets far less circulation than TRE's popularity would suggest, and it directly complicates any claim that TRE is a free upgrade over normal eating patterns.
Who this does not work for, or where the evidence is weakest: people trying to lose weight through TRE alone, without also reducing total calories, should not expect TRE to outperform normal eating, per the TREAT trial's own null result on weight [1]. Older adults and anyone at risk of muscle loss should be cautious given the lean-mass finding. People on medications timed to meals, including many diabetes and blood-pressure drugs, need clinical guidance before compressing their eating window. TRE research is also almost entirely short-duration, 8 to 12 weeks is typical; the ongoing NY-TREAT trial (Laferrere, Columbia, NCT04465721) is testing longer-term outcomes but had not reported final results at time of writing [3].
Mechanistically, TRE is proposed to work by aligning eating with circadian rhythm, since insulin sensitivity and thermogenesis both vary across the day, an idea championed by Panda's circadian biology lab underlying the Manoogian/Taub metabolic-syndrome trial [2]. That circadian framing is a more specific mechanism than plain calorie restriction, but the TREAT trial's null weight result suggests any circadian benefit, where it exists, shows up in glycemic markers before it shows up on the scale.
Plain takeaway: 16:8 time-restricted eating does not reliably beat normal-schedule eating for weight loss and comes with a documented lean-mass cost in at least one well-run RCT, but a longer eating-window variant (about 14 hours) shows a real, if modest, HbA1c improvement in people with metabolic syndrome. TRE is not a weight-loss shortcut; it may be a modest metabolic tool for a specific at-risk group.
Isocaloric test
A September 2026 randomized feeding study (N=39, ages around 60, BMI 35.2) put one group on 10-hour time-restricted eating and one on a 16-hour usual eating pattern for 12 weeks. Both groups ate the same calories. Weight fell 2.7% under TRE versus 2.5% under usual eating. Appetite hormones (leptin, adiponectin, ghrelin) and inflammatory markers (CRP, cortisol, sRAGE) showed no significant between-group differences. When calories are matched, eating-window timing by itself moved nothing measurable in 12 weeks.
References
Every numbered citation in this entry links here. Each reference links out to the primary source.
-
[1]
Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters (TREAT trial) Tier 1
RCT, N=141 randomized/105 completed, 12 weeks: 16:8 TRE showed no significant weight-loss advantage over 3-meal control and greater appendicular lean mass loss.
-
[2]
Time-Restricted Eating in Adults With Metabolic Syndrome Tier 1
NIH-funded RCT, ~14.2-hour eating window, HbA1c improved -0.10% (95% CI -0.19 to -0.003) vs control in metabolic syndrome patients.
-
[3]
NY-TREAT: Time-Restricted Eating in Adults with Overweight/Obesity Tier 3
Ongoing longer-duration TRE trial registration, cited for context on the limited duration of existing TRE evidence.
-
[4]
Time-restricted eating and cardiometabolic health: review Tier 3
Review synthesizing TRE trial evidence on cardiometabolic markers across multiple eating-window protocols.
-
[5]
Time-restricted feeding and circadian metabolic regulation Tier 3
Mechanistic review of circadian rationale underlying TRE, relevant to the Panda/Taub metabolic-syndrome trial design.
-
[6]
Alternate day fasting improves physiological and molecular markers of aging Tier 1
Cited for comparison of TRE against ADF's better-established metabolic benefit profile within the broader fasting-protocol literature.
-
[7]
Meta-analysis of 23 RCTs, N=1280 adults 18-59y. 16:8 TRE reduced fasting glucose SMD -0.25 (95% CI -0.42 to -0.08, P=.004) and HOMA-IR SMD -0.16 (95% CI -0.29 to -0.02, P=.03). Low-certainty evidence, heterogeneity I2=42-58%.
-
[8]
12-week single-center RCT, N=61 randomized (52 completed) adults with obesity BMI 30-50, baseline eating window >=14h/day. 10h-TRE lost 4.59 kg vs 1.68 kg standard of care, between-group difference -2.91 kg (95% CI -4.21 to -1.60), p<0.001. NCT04916730.
- [9]
Further reading
Curated external sources for a deeper dive. External links open in a new tab.
- TREAT trial, JAMA Internal Medicine JAMA
- TRE in metabolic syndrome, Annals of Internal Medicine secondary
- NY-TREAT trial registration ClinicalTrials.gov